Ventyx Biosciences, Inc. (NASDAQ:VTYX) Holdings Raised by Monaco Asset Management SAM

Monaco Asset Management SAM raised its holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 372.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,134,444 shares of the company's stock after purchasing an additional 894,444 shares during the quarter. Monaco Asset Management SAM owned 1.59% of Ventyx Biosciences worth $1,305,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in VTYX. American Century Companies Inc. boosted its position in Ventyx Biosciences by 12.4% during the 4th quarter. American Century Companies Inc. now owns 67,329 shares of the company's stock worth $147,000 after purchasing an additional 7,414 shares during the period. Geode Capital Management LLC boosted its position in Ventyx Biosciences by 1.5% during the 4th quarter. Geode Capital Management LLC now owns 1,413,039 shares of the company's stock worth $3,095,000 after purchasing an additional 21,337 shares during the period. Wells Fargo & Company MN boosted its position in Ventyx Biosciences by 23.3% during the 4th quarter. Wells Fargo & Company MN now owns 41,170 shares of the company's stock worth $90,000 after purchasing an additional 7,768 shares during the period. ADAR1 Capital Management LLC boosted its position in Ventyx Biosciences by 27.1% during the 4th quarter. ADAR1 Capital Management LLC now owns 124,530 shares of the company's stock worth $273,000 after purchasing an additional 26,575 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Ventyx Biosciences by 99.1% during the 4th quarter. Renaissance Technologies LLC now owns 624,500 shares of the company's stock worth $1,368,000 after purchasing an additional 310,800 shares during the period. Hedge funds and other institutional investors own 97.88% of the company's stock.

Ventyx Biosciences Trading Down 6.1%

NASDAQ:VTYX traded down $0.17 on Friday, reaching $2.63. The stock had a trading volume of 546,675 shares, compared to its average volume of 1,140,703. The company has a 50-day moving average of $2.46 and a 200 day moving average of $1.80. The stock has a market cap of $187.15 million, a P/E ratio of -1.50 and a beta of 0.97. Ventyx Biosciences, Inc. has a 12-month low of $0.78 and a 12-month high of $3.39.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.09. On average, equities analysts predict that Ventyx Biosciences, Inc. will post -2.09 EPS for the current year.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.